A 34-year-old female smoker (4 packs a year), with the following symptoms: dry cough, moderate dyspnea, fatigue, night sweats and no exposure to respiratory poisoning or contact with tuberculosis. Clinical findings at admission: normal temperature, Hippocratic fingers and cyanosis, diminished bilateral breath sounds, fine bilateral rattling respiratory sounds, rhythmic cardiac noises, oxygen saturation 95%, pulse 87, blood pressure 125/80 mm Hg. Chest computed tomography describes infiltration images of intra-alveolar and intra-bronchial with matte glass pattern, confluent and stretched across all lung segments. Pulmonary biopsy: preserved pulmonary architecture, thick alveolar septs and terminal bronchioles, alveoli and macrophages loaded with lipoprotein material. Bronchial aspirate: negative BAAR, no tumor cells. Bronchoalveolar lavage: opalescent, abundant PAS + appearance. total cell numbers -4.3 million, macrophages -34.1%, lymphocytes -56.9%, neutrophils -10%, eosinophils -0.4%, epithelial cells -33%.The treatment option chosen for this case was total bronchoalveolar lavage for therapeutic purposes. The patient had a rapid favourable evolution and at discharge was recommended a periodic imaging and functional control. Key Messages: Bronchoalveolar lavage is the optimal diagnostic method. Moderate/ severe forms, total bronchoalveolar lavage is recommended. Systemic corticotherapy or immunosuppression is not indicated. GM-CSF administered subcutaneously or by nebulization. Rituximab/ plasmapheresis are under evaluation. Pulmonary transplantation is indicated in patients who do not respond to therapeutic bronchoalveolar lavage repeated 6-12 months.
INTRODUCTION
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease that concerns pulmonary interstitium through an abnormal and excessive accumulation of surfactant inside the alveoli, which can affect gas exchange and can lead to dyspnea and limited efforts. 1 It is a diffuse pulmonary disease of unknown etiology and characterized by the accumulation in the distal airspace of a positive amorphous PAS lipoproteinate material that does not alter the pulmonary architecture. 2 The following forms of PAP have been defined: a) congenital PAP, where mutations may occur: GM-CSF receptor level, surfactant genes or a transport defect; b) secondary PAP, exposure caused by: exposure to dust, haematogenic diseases or allogeneic bone marrow transplantation. 3 In 30% of cases the PAP patients are asymptomatic. At pathophysiological level, an imbalance between the homeostatic mechanism by surfactant production and the alveolar macrophage clearance has been identified and that results in the accumulation of lipoproteinic material in the alveoli. Frequently PAP affects males at a ratio of 4:1, at an average age of 35 years. 4 
CASE HISTORY
A 34-year-old female smoker ( (Fig. 1) Chest computed tomography describes infiltra- (Fig. 4) .
After discussing smoking cessation methods, the treatment option chosen for this patient was total bronchoalveolar lavage for therapeutic purposes. 8 The patient had a rapid favourable evolution and at discharge was recommended a periodic imaging and functional control. At six-month evaluation, the patient's overall condition was within normal limits, but was regularly monitored for possible changes in the state of health. (Fig. 5 
DISCUSSION
In moderate or severe forms, total bronchoalveolar lavage is recommended. Systemic corticotherapy or immunosuppression is not indicated. Other variants of treatment: GM-CSF administered subcutaneously or by nebulization. Rituximab or plasmapheresis are under evaluation. Pulmonary transplantation is indicated in patients who do not respond to therapeutic bronchoalveolar lavage repeated at 6-12 months. 10 
CONCLUSION
Pulmonary alveolar proteinosis is a rare disease that poses difficulties in diagnosis through uncharacteristic symptoms. Differential diagnosis includes diseases with the same radiological aspect: cardiogenic pulmonary edema, pneumocystis jiroveci pneumonia, non-small cell lung cancer or small cell lung cancer, sarcoidosis. Bronchoalveolar lavage is the optimal diagnostic method. Treatment management depends on the progression of the disease. 9 
